ADVANCED LYMPHOMA
Clinical trials for ADVANCED LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LYMPHOMA trials appear
Sign up with your email to follow new studies for ADVANCED LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer care comes home: mayo clinic tests house calls for treatment
Disease control Recruiting nowThis study is testing whether giving standard cancer treatments at home is as safe and effective as giving them in a clinic. It aims to see if receiving care at home reduces stress, improves quality of life, and is preferred by patients with advanced cancers. About 220 participan…
Matched conditions: ADVANCED LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New cancer drug enters first human trials
Disease control Recruiting nowThis is the first study in people to test a new oral drug called AN4005 for patients with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find a safe and tolerable dose by giving the drug to small groups of patients at increas…
Matched conditions: ADVANCED LYMPHOMA
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo targets Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing the safety and effectiveness of a new two-drug combination for people with advanced solid tumors, including pancreatic cancer, that have spread or stopped responding to standard treatments. The trial aims to find the best dose and see if the drugs can help c…
Matched conditions: ADVANCED LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
First human test for promising new cancer pill
Disease control Recruiting nowThis is an early safety study for a new drug called TAK-243 in adults with advanced solid tumors or lymphoma. The main goal is to find the safest dose and understand the side effects. Researchers will give the drug to about 95 patients and closely monitor how their bodies handle …
Matched conditions: ADVANCED LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:23 UTC